Prescient Therapeutics Confirms First US Site for PTX-100 Phase 2a Refractory Cutaneous T-Cell Lymphoma Trial
Oncology biotech Prescient Therapeutics (ASX: PTX) has announced the completion of its first US site visit for...
Oncology biotech Prescient Therapeutics (ASX: PTX) has announced the completion of its first US site visit for...
Prescient Therapeutics Ltd CEO James McDonnell talked with Proactive about the company’s latest milestone —...
Prescient Therapeutics has reached a key milestone in its clinical development program, initiating its first...
The first United States clinical trial site for Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF)’s Phase 2a study...
Prescient Therapeutics has crossed a major milestone in its international expansion, with the first US...
Stockhead’s Tylah Tully catches up with Prescient Therapeutics (ASX:PTX) CEO James McDonnell after the company hit a...
Prescient Therapeutics CEO James McDonnell talked with Proactive about promising developments surrounding the company’s lead...
For those affected by Cutaneous T-Cell Lymphoma (CTCL), a rare and aggressive cancer, treatment options...
Prescient Therapeutics is focused on development of lead compound PTX-100 to treat rare blood cancer
Highlights,PTX-100 enters Phase 2 trial for relapsed and refractory Cutaneous T-Cell Lymphoma, Analysts lift valuation...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.